Preclinical Microfluidic Cell Squeezing for B-Cell Vaccines

Q: Can you deliver multiple types of cargo simultaneously using this platform?

Yes, our platform can optimize microfluidic channel geometry to deliver a cocktail of peptides, mRNA, and small-molecule modulators in a single pass to address tumor heterogeneity.

Q: What tumor models are best for evaluating squeezed B-cell vaccines?

We recommend syngeneic murine models like B16 or TC-1 (for HPV16+ studies) to validate antigen delivery and the induction of robust antitumor effector responses.

Q: Is this platform suitable for loading patient-specific neoantigens?

Absolutely. Our platform is ideal for precision medicine, enabling the identification and delivery of customized neoantigens into B cells for truly personalized vaccine candidates.

Redefining intracellular delivery via gentle mechanical deformation. Creative Biolabs provides an innovative microfluidic platform for B-cell based vaccines , leveraging microfluidic squeezing to achieve superior functional preservation.

Our platform overcomes the limitations of electroporation by using mechanical cell squeezing to deliver diverse cargoes—from tumor antigens to mRNA—directly into B cells. This high-throughput approach ensures maximal cell viability and robust immune priming, accelerating the development of potent cell-based immunotherapies.

Discuss Your Squeezing Strategy

Why Microfluidic Squeezing? A Functional Leap for B-Cell Engineering

As highlighted in recent 2023 npj Vaccines research (Wang et al.), microfluidic squeezing represents a paradigm shift in cell therapy. Our platform focuses on solving the viability-potency paradox:

▶ Gentle Membrane Permeabilization: Temporary pores are created via physical squeezing rather than harsh electrical pulses, preventing B-cell activation-induced apoptosis.
▶ Superior Cargo Diversity: Seamlessly deliver proteins, peptides, mRNA, or small molecule adjuvants simultaneously to target tumor heterogeneity.
▶ Industrial-Scale Throughput: Optimized micro-channel arrays allow for the processing of millions of B cells per minute with consistent preclinical quality.

Specialized Preclinical Development Solutions

We provide a fully integrated suite of assays to engineer high-performance B-cell vaccines via microfluidics:

Custom B-Cell Engineering

Strategic selection of B-cell subsets (e.g., Memory B cells, Naive B cells) and microfluidic channel optimization tailored for specific cell diameters and membrane stiffness.

Multivalent Cargo Loading

High-efficiency delivery of TAA peptides, neoantigen mRNA, or metabolic inhibitors into B cells to turn them into potent professional APCs.

Functional Preservation Profiling

Quantitative assessment of surface marker expression (CD19, CD80, MHC II) and B-cell receptor (BCR) signaling integrity post-squeezing.

In Vivo Protective Validation

Tracking the migration and antigen-presenting efficiency of squeezed B cells in syngeneic models, followed by T-cell recall and tumor volume monitoring.

Featured Preclinical Focus Areas

Advancing the boundaries of cell-based vaccines for high-risk clinical targets:

HPV16+ Solid Tumor Models

Leveraging SQZ-style PBMC loading logic to deliver E6/E7 antigens into B cells for the eradication of HPV-associated malignancies.

Explore HPV Models →

Neoantigen Delivery Logic

Utilizing microfluidic channels to load personalized mutation peptides into B cells, providing a comprehensive "cell-based seed" for immunotherapy.

View Precision Suites →

Mucosal Immunity Enhancement

Engineering B cells that preferentially migrate to mucosal-associated lymphoid tissues (MALT) to prevent infection-driven oncogenesis.

Learn About TME Reversal →

High-Throughput Prototypes

Developing standardized B-cell squeezing protocols that maintain functional consistency across millions of processed cells for preclinical dossiers.

Get Prototype Details →

Agile Preclinical Squeezing Development Workflow

Our systematic pipeline ensures the transition from raw microfluidic design to a validated cell-vaccine candidate:

Step 1: Microfluidic Device & Channel Optimization

Activities: Customizing the geometry of microfluidic channels based on the target B-cell diameter and stiffness. In silico modeling ensures the optimal "squeeze ratio" to maximize membrane porosity while maintaining structural integrity.

Outcome: Validated microfluidic blueprints optimized for your specific cell source.

Step 2: B-Cell Preparation & Cargo Design

Activities: High-purity isolation of B cells from peripheral blood or spleen. Optimization of cargo concentration (e.g., HPV E6/E7 peptides or tumor neoantigens) and buffer composition to maximize loading efficiency during the squeeze cycle.

Outcome: High-quality single-cell suspensions ready for high-throughput processing.

Step 3: High-Throughput Squeezing & Loading

Activities: Rapidly passing the B cells through the micro-channel arrays. We perform real-time monitoring of flow rates and temperature to ensure consistent mechanical stress and prevent cargo degradation.

Outcome: Cargo-loaded B cells with verified intracellular delivery signatures.

Step 4: Functional Recovery & APC Characterization

Activities: Post-squeeze incubation to allow for membrane repair. We utilize 18-parameter flow cytometry to assess viability, MHC class I/II presentation kinetics, and the secretion of pro-inflammatory cytokines like IL-12.

Outcome: Functional proof-of-concept for antigen-presenting capability.

Step 5: Syngeneic In Vivo Efficacy Analysis

Activities: Administration of squeezed B-cell vaccines into syngeneic murine models. We monitor tumor growth inhibition (TGI) and perform longitudinal immune kinetics tracking to identify lead efficacy markers for IND support.

Outcome: Final preclinical data package demonstrating protective antitumor potency.

Discuss Your Project Timeline

Core Cell Squeezing Engineering Platforms

Our solutions are powered by proprietary systems tailored for precision B-cell modulation:

Squeeze-Flow Engineering Hub: A sophisticated platform designed for the high-fidelity synthesis of microfluidic channel arrays. It ensures uniform mechanical stress across millions of B cells, preventing "burst" effects common with electrical methods.

Validated for multiple cell types (B cells, DCs, PBMCs)
Precise control over squeeze ratios and deformation time
High-throughput scalability for preclinical dossiers

Safe-Cargo Delivery Suite: Advanced loading platform focusing on the delivery of diverse intracellular modulators. It minimizes extracellular leakage and ensures the cargo is released directly into the cytosol for MHC I cross-presentation.

Dual-loading capabilities (Antigen + Adjuvant)
High cargo retention efficiency verified by mass spec
Optimized for complex cargoes like mRNA and large proteins

Immuno-Safe Monitoring Hub: A comprehensive analytical suite designed to assess the viability and functional integrity of squeezed B cells. This platform helps confirm that the physical deformation process does not trigger unwanted cellular stress signatures.

Real-time viability tracking via high-resolution imaging
Assessment of activation-induced cell death (AICD) markers
Longitudinal monitoring of B-cell APC functionality in vivo

Squeeze-Flow Hub

Safe-Cargo Suite

Immuno-Safe Hub

Scientific Insight: Transitioning to Clinical Investigation

Microfluidic Squeezing vs. Electroporation (Wang et al., 2023)

Innovation: Research published in npj Vaccines demonstrates the immense potential of mechanical cell squeezing for next-gen vaccines. The study highlights the platform's superiority in viability, functional preservation, and industrial scalability over traditional electroporation.

Research Highlights:

Technical Mechanism: Localized deformation creates temporary pores, enabling efficient cytosolic delivery of antigens for MHC I presentation.
Industry Application: Demonstrated via the SQZ-PBMC-HPV candidate, showcasing how concept-stage tools evolve into industrial production platforms.
Outcome: Proved effective in HPV16+ solid tumor models, demonstrating the ability of squeezed cells to induce robust, functional antitumor T-cell responses.

Technologic development of microfluidic mechanoporation for cellular delivery.

Fig.1 Microfluidic mechanoporation technology for efficient cellular delivery.^1,2

Frequently Asked Questions

Q: What is the primary advantage of cell squeezing over electroporation?

A: Electroporation uses high-voltage pulses that often cause irreversible membrane damage and cellular stress. Squeezing is purely mechanical and gentle, resulting in significantly higher cell viability (>90%) and preserving the B cell's natural ability to mature and prime T cells effectively.

Q: Can you deliver multiple types of cargo simultaneously using this platform?

A: Yes. One of the unique features of our platform is its versatility. We can optimize the micro-channel geometry to deliver a cocktail of peptides, mRNA, and even small-molecule metabolic modulators in a single pass, ensuring a multi-layered immune attack.

Q: Does the squeezing process affect B-cell surface marker expression?

A: Preclinical data show that microfluidic squeezing maintains high levels of critical costimulatory molecules like CD80, CD86, and MHC II. Our 'Immuno-Safe' platform rigorously monitors these markers to ensure the squeezed cells remain high-performance APCs.

Q: What tumor models are best for evaluating squeezed B-cell vaccines?

A: We recommend syngeneic murine models with well-characterized immune landscapes (e.g., CT26 or B16). We can also utilize HPV16-positive TC-1 models to validate antigen delivery and antitumor effector responses, mimicking recent successful clinical candidates.

Q: Is this platform suitable for loading patient-specific neoantigens?

A: Absolutely. Our platform is ideal for precision medicine. We can identify somatic mutations via NGS and use microfluidic squeezing to load these customized neoantigens into B cells, creating a truly personalized cell-based vaccine for preclinical research.

Related Resources

References:
1. Wang, Shuhang, et al. "Microfluidic cell squeeze-based vaccine comes into clinical investigation." npj Vaccines 8.1 (2023): 65.
2. Distributed under Open Access License CC BY 4.0, without modification.